Patents by Inventor Thomas von Rueden

Thomas von Rueden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs
    Patent number: 6855710
    Abstract: The present invention relates to new substituted indolinones of general formula wherein X and R1 to R5 are defined as in claim 1, the isomers and the salts thereof which have valuable properties. The above compounds of general formula I wherein R1 denotes a hydrogen atom, a C1-3-alkyl group or a prodrug group have valuable pharmacological properties, particularly an inhibiting effect on various kinases, on viral cyclin and on receptor tyrosine kinases, and the other compounds of the above general formula I wherein R1 does not represent a hydrogen atom, a C1-3-alkyl group or a prodrug group are valuable intermediate products for the preparation of the abovementioned compounds.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: February 15, 2005
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Rainer Walter, Wolfgang Grell, Armin Heckel, Frank Himmelsbach, Wolfgang Eberlein, Gerald Roth, Jacobus C.A. van Meel, Norbert Redemann, Walter Spevak, Ulrike Tontsch-Grunt, Thomas von Rueden
  • Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs
    Publication number: 20040058978
    Abstract: The present invention relates to new substituted indolinones of general formula 1
    Type: Application
    Filed: September 19, 2003
    Publication date: March 25, 2004
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Rainer Walter, Wolfgang Grell, Armin Heckel, Frank Himmelsbach, Wolfgang Eberlein, Gerald Roth, Jacobus C. A. van Meel, Norbert Redemann, Walter Spevak, Ulrike Tontsch-Grunt, Thomas von Rueden
  • Generation of specific binding partners binding to (poly)peptides encoded by genomic DNA fragments or ESTs
    Patent number: 6653068
    Abstract: The present invention relates to the generation of specific binding partners binding to (poly)peptides encoded by genomic DNA fragments or ESTs. The (poly)peptides are expressed as part of fusion proteins which are forming inclusion bodies on expression in host cells. The inclusion bodies are used to generate binding partners which bind specifically to said (poly)peptides. The specific binding partners, in particular immunoglobulins or fragments thereof, are useful for analysis and functional characterization of proteins encoded by nucleic acid sequences comprising the corresponding genomic DNA fragments or ESTs. The invention further relates to nucleic acid molecules, vectors and host cells to be used in the methods of the present invention.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: November 25, 2003
    Assignee: Morphosys AG
    Inventors: Christian Frisch, Titus Kretzschmar, Adolf Höss, Thomas Von Rüden